For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Combined airway valve therapy in severe emphysema improves lung function and walking distance for patients with heterogeneous disease, despite some risks.

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globallyCombined in-licensing and financing for a novel long-acting clinical ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...